12-week Initiation Program Complete Justin Reid, CEO of Troilus, commented "We've made excellent progress in recent months thanks to the strong collaboration between BBA and our internal project team. Finalizing the flowsheet on schedule marks a major milestone and speaks to the precision and discipline guiding our development approach. BBA's deep familiarity with the site and its track record on world-class projects like Canadian Malartic and Detour Lake, continues to add significant value. We look forward ...

SINGAPORE, June 10, 2025 /PRNewswire/ -- Canaan Inc. (NASDAQ: CAN) ("Canaan" or the "Company"), an innovator in crypto mining, today released its unaudited bitcoin mining update for the month ending May 31, 2025.Management Commentary"In May 2025, despite the 10% increase in tariffs on our Malaysia-made Bitcoin mining machines due to ongoing U.S. trade uncertainties, we remained focused on executing our strategic priorities with discipline and agility," said Nangeng Zhang, chairman and chief executive office ...

Asia Pacific LM Strategy 6-Jun-25 Asia Local Markets Strategy Emerging Markets Strategy Michael Loh AC michael.loh@jpmorgan.com JP Morgan Chase Bank, N.A., Singapore Branch See the end pages of this presentation for analyst certification and important disclosures, including non-US analyst disclosures. J.P. Morgan does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity ...

TORONTO, June 09, 2025 (GLOBE NEWSWIRE) -- Lithium Ionic Corp. (TSXV: LTH; OTCQX: LTHCF; FSE: H3N) (the “Company” or “Lithium Ionic”) reports that it has filed the independent NI 43-101 compliant technical report for its 100%-owned Bandeira Lithium Project (“Bandeira” or the “Project”) in Minas Gerais State, Brazil, related to the updated Mineral Resource Estimate (“MRE”) for the Project announced on May 6, 2025. The technical report, titled “Bandeira Lithium Project NI 43-101 Technical Report Mineral Resou ...

Step-up in basis raises an asset's cost basis to the fair market value on the day the owner dies. It also exempts it from capital gains taxes until sold after death. https://t.co/MeRFjv425M ...

Core Insights - SSR Mining Inc. has temporarily suspended operations at the Seabee mine in Canada due to power outages caused by nearby forest fires [1][8] - The Seabee mine produced 26,001 ounces of gold in Q1 2025, reflecting a year-over-year increase of 9.4% [2][8] - Despite the operational halt, SSR Mining's shares rose by 3% and reached a 52-week high of $13.33, driven by high gold and silver prices [4][8] Production and Financial Outlook - SSR Mining expects the Seabee mine to produce between 70,000 to 80,000 ounces of gold for the full year of 2025 [3] - The cost of sales for the mine is projected to be between $1,230 and $1,270 per payable ounce, with an all-in sustaining cost (AISC) anticipated to be between $1,710 and $1,750 per payable ounce for 2025 [3] Market Performance - Silver prices have reached a 13-year high above $36 per ounce, while gold prices have also seen significant increases, currently around $3,320 per ounce [5] - SSR Mining's share price has surged by 147.9% over the past year, contrasting with a 2.2% decline in the industry [7] Strategic Moves - The recent acquisition of the Cripple Creek & Victor mine from Newmont Corporation positions SSR Mining as the third-largest gold producer in the United States, expected to boost annual production by 170,000 ounces of gold [6]

Summary of Ascendis Pharma (ASND) Conference Call Company and Industry Overview - **Company**: Ascendis Pharma - **Industry**: Biotechnology, specifically focusing on treatments for growth disorders such as achondroplasia Key Findings from the COAST Trial - The COAST trial is a Phase II study assessing the efficacy of a combination therapy involving TransCon CNP and TransCon Growth Hormone in children with achondroplasia aged 2 to 11 years [2][3] - The trial reported a significant increase in annualized growth velocity (AGV) for treatment-naive children, achieving 9.14 cm/year, which is an increase of 4.2 cm/year compared to baseline [19][20] - For children previously treated with TransCon CNP, the AGV was 8.25 cm/year, reflecting a 3.1 cm/year increase from baseline [21][22] Efficacy and Safety Data - The combination therapy demonstrated a 0.53 increase in height Z score for treatment-naive patients and a 0.44 increase for treatment-experienced patients after 26 weeks [20][22] - The safety profile of the combination therapy was comparable to that of the individual therapies, with no serious adverse events related to the study drug reported [17][18] - The combination therapy resulted in a linear growth improvement associated with better body proportionality, which is crucial for children with achondroplasia [24][25] Future Development Plans - Ascendis Pharma plans to initiate a Phase III trial by the end of 2025, which will include both treatment-naive and experienced children [26][30] - The company aims to expand its treatment options for growth disorders and explore over 20 potential indications for its therapies [27][84] Market Position and Strategy - Ascendis Pharma is positioned as a leader in the growth disorder treatment market, with a focus on developing unique treatment combinations that unlock new therapeutic potentials [27][84] - The company is considering co-formulating TransCon CNP and TransCon Growth Hormone into a single injection for improved patient compliance [45][103] Additional Insights - The trial results indicate a potential for achieving catch-up growth in children with achondroplasia, which could normalize their height relative to parental expectations [80] - The combination therapy is expected to provide significant benefits beyond linear growth, addressing broader health concerns associated with achondroplasia [81][96] Conclusion - Ascendis Pharma's recent trial results highlight a promising advancement in the treatment of achondroplasia, with significant improvements in growth velocity and safety. The company is poised to expand its market presence and explore additional indications for its therapies, reinforcing its commitment to addressing growth disorders effectively.

Core Insights - Ascendis Pharma announced positive interim results from the COACH Trial, demonstrating that the combination of TransCon CNP and TransCon hGH significantly improves growth and body proportionality in children with achondroplasia after 26 weeks of treatment [2][4][12] Group 1: Clinical Trial Results - For treatment-naïve children, the combination treatment resulted in a mean annualized growth velocity (AGV) of 9.14 cm/year, with a height Z-score improvement of +0.53 over 26 weeks [1][12] - For children previously treated with TransCon CNP, the mean AGV was 8.25 cm/year, with a height Z-score improvement of +0.44 over the same period [1][12] - The combination treatment led to accelerated improvement in body proportionality, aligning with increased linear growth [1][12] Group 2: Safety and Tolerability - The safety and tolerability profile of the combination treatment was consistent with that of the individual monotherapies, with generally mild treatment-emergent adverse events (TEAEs) reported [1][4][12] Group 3: Trial Design and Future Plans - The COACH Trial is a Phase 2 open-label trial investigating the efficacy, safety, and tolerability of the combination treatment in children aged 2 to 11 years with achondroplasia [5] - The interim analysis will be followed by Week 52 data, expected in Q4 2025, with plans to initiate a Phase 3 trial in the same timeframe [5][11] Group 4: Product Information - TransCon CNP is under priority review by the FDA as a monotherapy for children with achondroplasia, while TransCon hGH is already approved and marketed as SKYTROFA for pediatric growth hormone deficiency [3][10] - Both products utilize Ascendis Pharma's innovative TransCon technology platform, which aims to provide sustained release of active compounds [3][10]

2025 年 6 月 9 日 行业研究 Optimus 项目负责人宣布离职，工程机械景气度持续复苏 ——机械行业周报 2025 年第 23 周（2025.6.2-2025.6.8） 机械行业 买入（维持） 作者 分析师：黄帅斌 执业证书编号：S0930520080005 0755-23915357 huangshuaibin@ebscn.com 分析师：陈佳宁 执业证书编号：S0930512120001 021-52523851 chenjianing@ebscn.com 分析师：汲萌 执业证书编号：S0930524010002 021-52523859 jimeng@ebscn.com 分析师：李佳琦 执业证书编号：S0930524070006 021-52523836 lijiaqi@ebscn.com 分析师：庄晓波 执业证书编号：S0930524070018 0755-25310400 zhuangxiaobo@ebscn.com 联系人：夏天宇 xiatianyu@ebscn.com 重点子行业观点 人形机器人： 6 月 7 日，东风柳州汽车有限公司与智平方（深圳）科技有限公司在深圳正式签署 战略合 ...

Core Insights - Markel Insurance has appointed Sucheng Chang as the new Managing Director for Asia Pacific, effective July 14, 2025 [1][2] - Chang will lead Markel International's Asia Pacific business, focusing on profitable growth and exceptional client service [2][4] - The Asia Pacific business has seen a 600% increase in Gross Written Premium (GWP) since 2019, with underwriting profitability improving and employee numbers rising by nearly 300% [3] Company Strategy - The Accelerate Asia Pacific strategy is central to Markel International's growth agenda, aiming to build on the momentum achieved in the region [4] - Chang's leadership is expected to enhance the company's presence in the US$300 billion GWP Asia-Pacific insurance market [4][3] Leadership Background - Sucheng Chang has extensive experience in scaling insurance operations in Asia, previously serving as CEO for Aon in Hong Kong and holding strategic roles at Liberty Mutual for over 13 years [4][3] - Chang holds an MBA from Yale University and a BA from Boston University, indicating a strong educational background [4]